RORay Osborne

Ray Osborne

*This is an algorithmically generated author record based on publicly available information.

Ray Osborne has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Allan L. Covens

    From the Odette Cancer Centre, Toronto, Ontario; University of Montreal, Montreal, Quebec, Canada; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Northwestern University Feinberg School of Medicine, Chicago, IL; University of Oklahoma, Oklahoma City, OK; Duke University, Raleigh, NC; University of Pittsburgh, Pittsburgh, PA; University of Texas Southwestern Medical Center, Dallas, TX; and Medical University of South Carolina, Charleston, SC

    1 shared publication
  • Angeles Alvarez Secord

    From the Odette Cancer Centre, Toronto, Ontario; University of Montreal, Montreal, Quebec, Canada; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Northwestern University Feinberg School of Medicine, Chicago, IL; University of Oklahoma, Oklahoma City, OK; Duke University, Raleigh, NC; University of Pittsburgh, Pittsburgh, PA; University of Texas Southwestern Medical Center, Dallas, TX; and Medical University of South Carolina, Charleston, SC

    1 shared publication
  • David Scott Miller

    University of Texas Southwestern Medical Center, Dallas, TX

    1 shared publication
  • Diane Provencher

    From the Odette Cancer Centre, Toronto, Ontario; University of Montreal, Montreal, Quebec, Canada; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Northwestern University Feinberg School of Medicine, Chicago, IL; University of Oklahoma, Oklahoma City, OK; Duke University, Raleigh, NC; University of Pittsburgh, Pittsburgh, PA; University of Texas Southwestern Medical Center, Dallas, TX; and Medical University of South Carolina, Charleston, SC

    1 shared publication
  • Genevieve Bouchard-Fortier

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1E2, Canada

    1 shared publication
  • Gulisa Turashvili

    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    1 shared publication

Latest Publications

  • Gestational trophoblastic disease: an update

    by Tanya Chawla, Genevieve Bouchard-Fortier, Gulisa Turashvili, Ray Osborne, Kalesha Hack, Phyllis Glanc

    Gestational trophoblastic diseases (GTD) encompass a spectrum of rare pre-malignant and malignant entities originating from trophoblastic tissue. This updated review will highlight important radiological features, pathology and classification, and provide insight into the clinical management of these uncommon disorders. There is a wide geographic variation with the incidence of hydatidiform mole varying between 0.57 and 2 per 1000 pregnancies. The use of ultrasound (US) in the management of early pregnancy symptoms and complications has positively impacted the earlier detection of these diseases and resulted in diminished morbidity. Additional imaging modalities are reserved for problem solving or assessment of pulmonary manifestations of molar pregnancy. Having an awareness of their pleomorphic sonographic presentation and additional pathology that can mimic GTD is critical to avoiding pitfalls. Histologic and molecular analysis further aids in differential diagnosis. Gestational trophoblastic neoplasia (GTN) is inclusive of all malignant GTDs, and arises after 20% of molar pregnancies but can also be seen with non-molar gestations. Biochemical monitoring with human chorionic gonadotrophin is imperative for ongoing monitoring and surveillance and allows early detection of this entity. Doppler US is used for confirmation of diagnosis with magnetic resonance imaging (MRI) reserved for problem solving or assessment of myometrial invasion. This is of heightened relevance in patients undergoing surgical management. Cross sectional imaging is reserved for patients in the setting of GTN for the purposes of staging, prognostication and in the setting of recurrent disease. This may require a combination of computed tomography, MRI and positron emission tomography. Doppler US can provide insight into chemotherapeutic response/predict resistance in patients with GTN. As our understanding of these disorders evolves, there has been maturation in management options with a shift from traditional chemotherapy to innovative immunotherapy, particularly in the setting of resistant or high-risk disease.


  • Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study

    by Raymond J. Osborne, Virginia Filiaci, Julian C. Schink, Robert S. Mannel, Angeles Alvarez Secord, Joseph L. Kelley, Diane Provencher, David Scott Miller, Allan L. Covens, Janice M. Lage

    Purpose: There is no consensus on the best regimen for the primary treatment of low-risk gestational trophoblastic neoplasia (GTN). Patients and Methods: Two commonly used single-drug regimens were compared with respect to the proportion of patients meeting the criteria for a complete response (CR) in a randomized phase III trial conducted by the Gynecologic Oncology Group. Eligibility was purposefully broad to maximize the generalizability of the results and included patients with a WHO risk score of 0 to 6 and patients with metastatic disease (limited to lung lesions < 2 cm, adnexa, or vagina) or choriocarcinoma. Results: Two hundred forty women were enrolled, and 216 were deemed eligible. Biweekly intravenous dactinomycin 1.25 mg/m2 was statistically superior to weekly intramuscular (IM) methotrexate 30 mg/m2 (CR: 70% v 53%; P = .01). Similarly, in patients with low-risk GTN as defined before the 2002 WHO risk score revisions (risk score of 0 to 4 and excluding choriocarcinoma), response was 58% and 73% in the methotrexate and dactinomycin arms, respectively (P = .03). Both regimens were less effective if the WHO risk score was 5 or 6 or if the diagnosis was choriocarcinoma (CR: 9% and 42%, respectively). There were two potential recurrences; one at 4 months (dactinomycin) and one at 22 months (methotrexate). Not all patients completed follow-up. Both regimens were well tolerated. Conclusion: The biweekly dactinomycin regimen has a higher CR rate than the weekly IM methotrexate regimen in low-risk GTN, a generally curable disease.